Log in
NASDAQ:IOVA

Iovance Biotherapeutics Stock Forecast, Price & News

$37.65
+0.90 (+2.45 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.60
Now: $37.65
$37.79
50-Day Range
$28.04
MA: $33.11
$37.86
52-Week Range
$18.70
Now: $37.65
$41.49
Volume838,689 shs
Average Volume1.78 million shs
Market Capitalization$5.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.97
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Read More
Iovance Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120
Employees88

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.37 per share

Profitability

Net Income$-197,560,000.00

Miscellaneous

Market Cap$5.51 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$37.65
+0.90 (+2.45 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock price been impacted by Coronavirus?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IOVA shares have increased by 27.3% and is now trading at $37.65.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iovance Biotherapeutics
.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Iovance Biotherapeutics
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05.
View Iovance Biotherapeutics' earnings history
.

What price target have analysts set for IOVA?

11 brokers have issued twelve-month price objectives for Iovance Biotherapeutics' stock. Their forecasts range from $35.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $45.60 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price.
View analysts' price targets for Iovance Biotherapeutics
.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seattle Genetics (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.47%), Peregrine Capital Management LLC (0.25%), First Midwest Bank Trust Division (0.05%), FNY Investment Advisers LLC (0.02%), Sanders Morris Harris LLC (0.01%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends for Iovance Biotherapeutics
.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Peregrine Capital Management LLC, Vigilare Wealth Management, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Iovance Biotherapeutics
.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, First Midwest Bank Trust Division, Sanders Morris Harris LLC, Bellecapital International Ltd., Pacer Advisors Inc., Envestnet Asset Management Inc., and Larson Financial Group LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum.
View insider buying and selling activity for Iovance Biotherapeutics
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $37.65.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $5.51 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.